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Abstract 
Aims In isolated rat heart perfusion experiments, drug admin-
istration occurs via retrograde perfusion. This can be done in 
the non-recirculating mode (coronary effluent is discarded), or 
recirculating mode (coronary effluent is collected and reused). 
It was recently observed in our lab whi le using sanguinarine, 
an MKP- 1 inhibitor, that there were differences in outcomes 
depending on the mode of recirculation used. 
Methods and Results Hearts from control (C); diet-induced 
obese (DIO) Wistar rats and their age matched controls 
(AMC) were perfused on the rig. Hearts received buffer 
(control), insulin, sanguinarine, insulin + sanguinarine 
combination or methanol (vehicle) for 15mins pre- and IOmins 
post-ischemia in either a non- or re-circulating manner. Hearts 
were subjected to I 5mins global ischemia and 30mins reperfu-
sion. Mechanical function was documented pre- and post-
ischemia When not-recirculated, sanguinarine alone and in 
combination with insulin in C, DIO and AMC groups, caused 
a significant decrease in functional recovery during reperfusion. 
However, when the coronary effluent was recirculated, hearts 
perfused with sanguinarine or sanguinarine + insulin exhibited 
a significant recovery in function when compared with their 
non-recirculation counterparts (p<0.01). No differences were 
seen with either control, insulin nor vehicle hearts. 
Conclusion Sanguinarine elicited a vast improvement in per-
fus ion outcomes when recirculated compared to non-
recirculation. Since this was seen during perfusion only 
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w hen sanguinarine was present, it is possible that 
recirculating reperfusion of the drug caused profound 
changes in its compos ition. More invest igation is 
needed into the mechanisms involved. Thus caution 
should be exercised by researchers when designing a 
perfusion protocol for drug research. 
Keywords Isolated heart perfusions · Drug recirculation · 
lschaemia/reperfusion injury 
Introduction 
The Langendorffperfusion technique has been used extensively 
for decades in cardiovascular research, especially when there is 
a need to administer drugs to the heart during perfusion [I]. 
This can be done in either a recirculating or non-recirculating 
mode [2, 3). Because of the large volumes of perfusion flu id 
required during an experimental protocol, and the high cost of 
some drugs that are used, working protocols often operate in the 
recirculating mode [ 4), however this is not always the case [5]. 
Sanguinarine is an alkaloid derived from the roots of 
Sanguinaria canadendid and has been found to activate 
AMP-activated protein kinase (AMPK) [6] and inactivate 
mitogen-activated protein kinase phosphatase- I (MKP- 1) 
[7). In our laboratory sanguinarine is used as an MKP-1 
inhibitor, in a study to elucidate the involvement of MKP-1 
in insulin stimulated cardioprotection. It is known that insulin 
offers protection to the heart during ischaemia/reperfusion and 
increases post ischaemic recovery [8). However, the role of 
MKP-1 in this pathway is unknown under normal circum-
stances as well as in obesity and insulin resistance. 
In our study, sanguinarine was initially administered in the 
non-recirculating mode; however, due to the high costs in-
volved, the perfusion was switched to the recirculating mode. 
To our surprise, we observed that, when the drug was admin-
istered in the recirculating mode, it y ielded different results 
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from when it was given in the non-recirculating mode. This 
prompted us to pursue this phenomenon to distinguish wheth-
er the effect was seen with all the drug interventions we used 
or only with sanguinarine. 
Our aim was thus to establish whether the perfusion mode 
(recirculating or non-recirculating) had an effect on functional 
recovery after ischaemia. Hearts from young control rats, 
dietary induced obese rats and their age matched controls were 
perfused in the presence of sanguinarine, insulin and/or the 
vehicle (methanol). 
Methods 
Animals 
Male Wistar rats were used. Rats weighing between 200-220 g 
served as controls. A separate group of rats was divided into 
two subgroups and either fed a high caloric diet for 16 weeks 
(dietary induced obese, DIO) or used as the age matched 
controls (AMC) which received standard rat chow. The project 
was approved by the Committee of Experimental Animal 
Research of the Faculty of Health Sciences, Stellenbosch 
University and complied with the guidelines of the revised 
South African National Standard for the Care and Use of 
Animals for Scientific Purposes (SANS I 0386, 2008 - P08/ 
051005) and the guidelines from Directive 20 I 0/63/EU of the 
European Parliament on the protection of animals used for 
scientific purposes. The rats were allowed free access to food 
and water, and maintained in Stellenbosch University's Central 
Research Facility at 22 °C with a 12 h day/night cycle. 
Isolated Heart Perfusion Methodology 
Animals were injected with an overdose ofEuthenase (sodium 
pentobarbitone, 0. 12 mg per gram body weight). Once ani-
mals were anaesthetized and completely unresponsive as con-
fim1ed by foot pinching, hearts were excised, arrested in cold 
(4°C) Krebs-Henseleit buffer (KHB, 11 9 mM NaCl, 25 mM 
NaHC03, 4 .75 mM KCI, 1. 185 mM KH2P04, 0.6 mM 
MgS04, 0.6 mM NaS04, 1.25 mM CaC12.2H20, I 0 mM glu-
cose) and mounted on a working rat heart perfusion system. 
The isolated hearts were perfused with KHB equilibrated with 
95%02/5%C02 at 37 °C. After I Omins stabilisation (retro-
grade perfusion), the heart was switched to perfusion in work-
ing mode for 20mins and mechanical function documented 
[(coronary flow (CF), aortic output (AO), cardiac output (CO 
= CF + AO), heart rate (HR), aortic systolic pressure (SP) and 
aortic diastolic pressure (DP)). Total work (TW) was calculat-
ed as a function of the cardiac output and systolic pressure 
(TW = COxSPx0.0022). The hearts were then perfused retro-
gradely for I 5mins either w ith KHB (Control), or with the 
following interventions: 
Insulin ( I mIU/ml), sanguinarine (2 µM), Insulin (I mJU/ml) 
+ sanguinarine (2 µM) (S + I), Methanol (vehicle control for 
sanguinarine) (0.01 %). 
Global ischaemia was then induced by stopping perfusion 
of the retrogradely perfused heart for 15 min. The temperature 
was maintained at 36.6 °C. Hearts were reperfused and treated 
with KHB (control) or the abovementioned interventions for a 
further I Omins in retrograde mode, and then in working heart 
mode for a further 20mins and mechanical function again 
documented. The percentage recovery was then calculated 
by expressing the post ischaemic total work as a percentage 
of the pre- ischaemic total work. 
Statistical Analyses 
Data was analysed using Microsoft GraphPad Prism. The one 
way analysis of variance ANOVA was used for comparison 
between all groups. All values are expressed as mean ± 
standard error of the mean (SEM). N values were between 6 
and 8 for all groups. A p-value smaller than 0.05 was consid-
ered significant. 
Results 
Control Hearts 
When the total work (TW) recovery of the 200- 220 g control 
rats was analysed it was seen that non-recirculation versus 
recirculation of control (61.9±6.7 vs 48. l ±4.9 %), insulin 
(46.6±5.4 vs 53.6±5.2 %); methanol (vehicle) (63.9± 7.02 
Tuble I Table to show all values for total work recovery in control 
(200 g), 010 and AMC rats 
Non recirculating Recirculating 
CONTROL (200 g) Control 48. 1±4.9 61 .9±6 
11 =6-8 Insulin 53.6±5.2 46.6±5.4 
Methanol 46. 1±4.8 63.9±7.02 
Sanguinarine 18.5±5.9 46.1±3.1. 
S+ I 38±8.7 37.02±9.3 
01011=6-8 Control 40±9.8 50.5±21.9 
Insulin 73.2± 10.8 95.5±4.5 
Methanol 86±4.02 61.1 ± 17.3 
Sanguinarine 8.5±6.4 67. 1±4.6 * 
S + I 18.3 ±7.7 47.1 ±7* 
AMCn=6-8 Control 56.01 ±6.7 35.8±30.7 
Insulin 83.6±3.9 87.8±2.3 
Methanol 84.1± 10.1 78.8±12.6 
Sanguinarine 13.1 ± 13.I 84.2±5.6 * 
S+ I 7.2±3.9 69.1±8.7 * 
* = p <0.05 in comparison to non-recirculated values. 
vs 46. 1 ±4.8 %) and S+I (38.3±8.7 vs 37.02±9.3 %) hearts 
showed no difference in total work recovery. However, when 
sanguinarine recirculation was compared to non-recirculation 
the total work recovery was significantly improved, with non-
recirculation values (18.5±5.9 %) being significantly lower 
than recirculated functional recovery (46.l ±3. l %) (p<O.O I) 
(Table l). 
DIO and AMC Hearts 
In both DIO and AMC hearts, neither control, insulin nor 
methanol differed in TW recovery between non-recirculated 
and recirculated modes of perfusion. DIO (non recirculated vs 
recirculated): control: 40±9.8 vs 50.5±21.9 %; insulin: 73.2± 
10.8 % vs 95.5±4.5 %; methanol: 86.4±5.02vs6I. I± 17.3 % 
and AMC: control: 56.01 ±6.7 vs 35.8±30.7 %; insulin: 83.6 
±3.9 vs 87.8±2.3 %; methanol: 84.1 ± IO. I vs 78.8± 12.6 %. 
However both sanguinarine alone and in combination with 
insulin had increased TW recovery in the recirculated as 
compared to the non- recirculated perfusion modes. DIO 
(non- recirculated vs recirculated): sanguinarine: 8.5±6.4 vs 
67.1±4.6 %; S+I: 18.3 ±7.7 vs 47.1±7 % and AMC 
sanguinarine: 13.1± 13.1 vs 84.2±5.6 %; S+I: 7.2±3.9 vs 
69. 1 ±8.7 % (p<O.Ol)(Table !). 
Discussion 
The data show that in the case of sanguinarine the mode of 
reperfusion has a profound effect on functional recovery dur-
ing reperfusion; with recirculation showing improved recov-
ery compared to non-recirculation. This was not evident in 
any of the other interventions used. While there were differ-
ences between interventions e.g. insulin improved functional 
recovery in the older animals, the focal point of this article is 
to show how variances in outcomes can occur with the same 
drug with different modes of delivery. 
It has been shown that coronary effluent from hearts which 
have undergone prior ischaemic preconditioning contained 
cytoprotective factors that, when transferred to other hearts, 
offers protection (9). However to our knowledge our study is 
novel in that the hearts were not preconditioned, the coronary 
effluent was used on the same hearts by which it was produced 
and sanguinarine was the only drug used which caused this 
effect. This could be due to the fact that sanguinarine is rapidly 
metabolised by the heart into an innocuous compound during 
recirculation, and only when the heart has a constant supply of 
the drug (as occurs during perfusion in the non recirculation 
mode) is it able to effect changes. It has been demonstrated that 
rats metabolise sanguinarine into non toxic dihydrosanguinarine 
in vivo [JO). The results obtained in our in vitro study, suggest 
that the isolated heart can metabolize this cytotoxic compound. 
While a small increase in coronary flow was observed with 
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sanguinarine administration (results not included), this 
occurred in both recirculation and non-recirculation modes, 
meaning that an increase in circulation is not the reason for the 
phenomenon seen. 
The value of these observations lies in the fact that 
the perfusion mode can affect the outcome of a study 
and should be taken into account by the researcher 
when planning a protocol. In this study the recirculation 
showed improved recovery, however the opposite could be 
true for other drugs. 
In conclusion, researchers, pham1aceutical companies, 
drug developers and clinicians should be wary of this possi-
bility when planning pre-dinical laboratory research and 
extrapolating the results towards clinical trials. 
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